Equities

Venus Remedies Ltd

VENUSREM:NSI

Venus Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)342.10
  • Today's Change-1.90 / -0.55%
  • Shares traded18.30k
  • 1 Year change+46.20%
  • Beta1.8722
Data delayed at least 15 minutes, as of Sep 20 2024 11:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments838713458
Total Receivables, Net1,4791,255671
Total Inventory1,2381,2291,256
Prepaid expenses6.346.74--
Other current assets, total3425395
Total current assets3,5953,2302,780
Property, plant & equipment, net1,5441,6281,782
Goodwill, net------
Intangibles, net852792879
Long term investments0.18--22
Note receivable - long term------
Other long term assets232340327
Total assets6,2686,0115,798
LIABILITIES
Accounts payable441508543
Accrued expenses6660--
Notes payable/short-term debt263641
Current portion long-term debt/capital leases--01.02
Other current liabilities, total260221343
Total current liabilities794826927
Total long term debt387387387
Total debt413423428
Deferred income tax1091060
Minority interest------
Other liabilities, total1038880
Total liabilities1,3931,4071,394
SHAREHOLDERS EQUITY
Common stock134134134
Additional paid-in capital883883--
Retained earnings (accumulated deficit)3,8193,5364,271
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total4050--
Total equity4,8764,6034,404
Total liabilities & shareholders' equity6,2686,0115,798
Total common shares outstanding131313
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.